Acridine carboxamide

Acridine carboxamide

Identifiers
IUPAC name N-[2-(Dimethylamino)ethyl]-4-acridinecarboxamide
CAS Number	89459-25-6
PubChem CID	107805
ChemSpider	96954
UNII	0N3V8R4E13
CompTox Dashboard (EPA)	DTXSID60237739
Chemical and physical data
Formula	C18H19N3O
Molar mass	293.370 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)CCNC(=O)C1=CC=CC2=CC3=CC=CC=C3N=C21
InChI InChI=1S/C18H19N3O/c1-21(2)11-10-19-18(22)15-8-5-7-14-12-13-6-3-4-9-16(13)20-17(14)15/h3-9,12H,10-11H2,1-2H3,(H,19,22) Key:XBGNERSKEKDZDS-UHFFFAOYSA-N

Acridine carboxamide is a chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.^{[ citation needed ]}

While the agent was well tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers. ^{[1] [2] [3] [4]}

See also

• Ondansetron, an isomer of Acridine carboxamide

References

1. Dittrich C, Dieras V, Kerbrat P, Punt C, Sorio R, Caponigro F, et al. (August 2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational New Drugs. 21 (3): 347–52. doi:10.1023/A:1025476813365. PMID   14578683. S2CID   19095200.
2. Caponigro F, Dittrich C, Sorensen JB, Schellens JH, Duffaud F, Paz Ares L, et al. (January 2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". European Journal of Cancer. 38 (1): 70–4. doi:10.1016/S0959-8049(01)00336-7. PMID   11750842.
3. Twelves C, Campone M, Coudert B, Van den Bent M, de Jonge M, Dittrich C, et al. (May 2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Annals of Oncology. 13 (5): 777–80. doi: 10.1093/annonc/mdf121 . PMID   12075748.
4. Dittrich C, Coudert B, Paz-Ares L, Caponigro F, Salzberg M, Gamucci T, et al. (February 2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". European Journal of Cancer. 39 (3): 330–4. doi:10.1016/S0959-8049(02)00559-2. PMID   12565985.